Home › Companies › 10X GENOMICS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and 10X GENOMICS INC.’s Form 8-K, filed June 13, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 11, 2024: 4 items on 10X GENOMICS INC.’s Form 8-K, filed June 13, 2024: 2 approved · 1 passed (calculated) · 1 not approved.
No notable dissent beyond the items above.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore 10X GENOMICS INC. in the interactive database Compare manager voting policies
These tallies are 10X GENOMICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 13, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Kimberly J. Popovits | 198,553,136 | 18,689,301 | 125,755 | -- | 11,864,638 | 91% | Passed (calculated) | — |
| 2. Ratification of Independent Registered Public Accounting Firm | 228,845,897 | 174,119 | 212,814 | -- | -- | 99.9% | Approved | — |
| 3. Vote to Approve an Amendment to the Company's Amended and Restated Bylaws to Permit the Company's Board of Directors to Amend the Company's Amended and Restated Bylaws Without Requiring Stockholder Approval | 112,727,437 | 104,506,389 | 134,366 | -- | 11,864,638 | 51.9% | Not approved A stricter vote than a majority of the votes cast may have applied to this item; the filing does not state it. | — |
| 4. Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers | 180,775,070 | 36,417,839 | 175,283 | -- | 11,864,638 | 83% | Approved | — |
Source: 10X GENOMICS INC., Form 8-K, filed with the SEC on June 13, 2024 — read the filing on EDGAR.
See voting trends for Industrials companies, 2023-2024: shareholder support by sector and by company size.
347 asset managers disclosed a vote on at least one 10X GENOMICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Election of the one Class II director listed in the accompanying proxy statement, to serve a three-year term expiring at the 2027 annual meeting of stockholders or until such director's successor is duly elected and qualified or until such director's earlier death, resignation, disqualification or removal; Kimberly J. Popovits
10X GENOMICS INC.’s own tally for this item (“Elect Director: Kimberly J. Popovits”): 198,553,136 for, 18,689,301 against, per its Form 8-K filed June 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 77 asset managers below reported 40,144,209 for, 7,034,283 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 13,458,118 | 1,519,256 | 0 | 0 | Mixed |
| Vanguard | 10,384,989 | 0 | 0 | 0 | For |
| ARK ETF Trust | 6,004,325 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 3,881,668 | 0 | 0 | Against |
| BlackRock | 1,706,915 | 0 | 0 | 0 | For |
| Morgan Stanley | 1,614,212 | 0 | 0 | 0 | For |
| Brown Capital Management Mutual Funds | 1,249,511 | 0 | 0 | 0 | For |
| Charles Schwab | 940,460 | 0 | 0 | 0 | For |
| Capital Group | 793,300 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 691,105 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 648,000 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 418,141 | 0 | 0 | 0 | For |
| BNY Mellon | 0 | 408,754 | 0 | 0 | Against |
| ALGER FUNDS | 0 | 360,492 | 0 | 0 | Against |
| Transamerica | 259,375 | 37,809 | 0 | 0 | Mixed |
| Voya | 287,987 | 0 | 0 | 0 | For |
| TIAA | 0 | 249,365 | 0 | 0 | Against |
| BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND) | 240,000 | 0 | 0 | 0 | For |
| Equitable | 149,465 | 47,828 | 0 | 0 | Mixed |
| Putnam | 191,656 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 158,214 | 0 | 0 | 0 | For |
| Jackson National | 62,559 | 80,998 | 0 | 0 | Mixed |
| Russell Investments | 138,599 | 0 | 0 | 0 | For |
| Brighthouse | 110,630 | 16,376 | 0 | 0 | Mixed |
| John Hancock | 0 | 117,462 | 0 | 0 | Against |
Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
51.9% Not approved · of votes cast
Description as filed by funds: A vote to approve an amendment to our amended and restated bylaws such that the bylaws may be amended by our board of directors without requiring stockholder approval;
10X GENOMICS INC.’s own tally for this item (“3. Vote to Approve an Amendment to the Company's Amended and Restated Bylaws to Permit the Company's Board of Directors to Amend the Company's Amended and Restated Bylaws Without Requiring Stockholder Approval”): 112,727,437 for, 104,506,389 against — failed, per its Form 8-K filed June 13, 2024 (Item 5.07). This item required more than a simple majority of votes cast — see the filing.
Reported outcome: Not approved, in the filing’s own words: “Proposal 3 - Vote to Approve an Amendment to the Company's Amended and Restated Bylaws to Permit the Company's Board of Directors to Amend the Company's Amended and Restated Bylaws Without Requiring Stockholder Approval The Company's stockholders did not approve a proposed amendment to the Company'…”
A stricter vote than a majority of the votes cast may have applied to this item; the filing does not state it.
Support: 51.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 77 asset managers below reported 11,455,634 for, 35,722,858 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 14,977,374 | 0 | 0 | Against |
| Vanguard | 1,436,878 | 8,948,111 | 0 | 0 | Mixed |
| ARK ETF Trust | 6,004,325 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 3,881,668 | 0 | 0 | Against |
| BlackRock | 0 | 1,706,915 | 0 | 0 | Against |
| Morgan Stanley | 0 | 1,614,212 | 0 | 0 | Against |
| Brown Capital Management Mutual Funds | 1,249,511 | 0 | 0 | 0 | For |
| Charles Schwab | 940,460 | 0 | 0 | 0 | For |
| Capital Group | 0 | 793,300 | 0 | 0 | Against |
| TOUCHSTONE FUNDS GROUP TRUST | 0 | 691,105 | 0 | 0 | Against |
| FRANKLIN STRATEGIC SERIES | 648,000 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 418,141 | 0 | 0 | Against |
| BNY Mellon | 0 | 408,754 | 0 | 0 | Against |
| ALGER FUNDS | 0 | 360,492 | 0 | 0 | Against |
| Transamerica | 0 | 297,184 | 0 | 0 | Against |
| Voya | 0 | 287,987 | 0 | 0 | Against |
| TIAA | 249,365 | 0 | 0 | 0 | For |
| BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND) | 0 | 240,000 | 0 | 0 | Against |
| Equitable | 0 | 197,293 | 0 | 0 | Against |
| Putnam | 191,656 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 158,214 | 0 | 0 | 0 | For |
| Jackson National | 10,633 | 132,924 | 0 | 0 | Mixed |
| Russell Investments | 138,599 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 127,006 | 0 | 0 | Against |
| John Hancock | 0 | 117,462 | 0 | 0 | Against |
Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).
Combines 11 wordings of this item as funds reported it.
83% Approved · of votes cast
Prior year: 82.8% for (June 14, 2023 meeting) ▲ 0.4 pts
Description as filed by funds: A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers; and
10X GENOMICS INC.’s own tally for this item (“4. Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers”): 180,775,070 for, 36,417,839 against — passed, per its Form 8-K filed June 13, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 4 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as described in more detail in the Company's definitive proxy state…”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 13,406,358 | 1,571,016 | 0 | 0 | Mixed |
| Vanguard | 8,948,111 | 1,436,878 | 0 | 0 | Mixed |
| ARK ETF Trust | 6,004,325 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,442,195 | 2,439,473 | 0 | 0 | Mixed |
| BlackRock | 0 | 1,706,915 | 0 | 0 | Against |
| Morgan Stanley | 1,608,406 | 5,806 | 0 | 0 | For |
| Brown Capital Management Mutual Funds | 0 | 1,249,511 | 0 | 0 | Against |
| Charles Schwab | 0 | 940,460 | 0 | 0 | Against |
| Capital Group | 0 | 793,300 | 0 | 0 | Against |
| TOUCHSTONE FUNDS GROUP TRUST | 691,105 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 648,000 | 0 | 0 | Against |
| Columbia Threadneedle | 418,141 | 0 | 0 | 0 | For |
| BNY Mellon | 23,778 | 384,976 | 0 | 0 | Mixed |
| ALGER FUNDS | 0 | 360,492 | 0 | 0 | Against |
| Transamerica | 259,375 | 37,809 | 0 | 0 | Mixed |
| Voya | 287,987 | 0 | 0 | 0 | For |
| TIAA | 0 | 249,365 | 0 | 0 | Against |
| BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND) | 0 | 240,000 | 0 | 0 | Against |
| Equitable | 142,987 | 54,306 | 0 | 0 | Mixed |
| Putnam | 0 | 191,656 | 0 | 0 | Against |
| AMERICAN BEACON FUNDS | 158,214 | 0 | 0 | 0 | For |
| Jackson National | 66,801 | 76,756 | 0 | 0 | Mixed |
| Russell Investments | 0 | 138,599 | 0 | 0 | Against |
| Brighthouse | 110,630 | 16,376 | 0 | 0 | Mixed |
| John Hancock | 0 | 117,462 | 0 | 0 | Against |
Fund voting reports, all 74 managers: 33,736,240 for, 13,423,075 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 16,988,131 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,088,709 | 3,278,557 | 0 | 0 | Mixed |
| BAILLIE GIFFORD & CO LTD | 0 | 3,850,099 | 0 | 0 | Against |
| Nikko Asset Management Americas, Inc. | 0 | 3,816,669 | 0 | 0 | Against |
| Morgan Stanley | 3,465,195 | 0 | 0 | 0 | For |
| BlackRock | 60,877 | 2,541,148 | 0 | 0 | Against |
| SANDS CAPITAL MANAGEMENT, LLC | 2,288,051 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD OVERSEAS LTD | 0 | 1,889,073 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 1,635,730 | 0 | 0 | Against |
| BROWN CAPITAL MANAGEMENT LLC | 0 | 1,598,610 | 0 | 0 | Against |
| UBS | 0 | 1,354,213 | 0 | 0 | Against |
| RTW INVESTMENTS, LP | 1,208,066 | 0 | 0 | 0 | For |
| GENERATION INVESTMENT MANAGEMENT LLP | 0 | 975,905 | 0 | 0 | Against |
| Charles Schwab | 0 | 944,952 | 0 | 0 | Against |
| FRANKLIN ADVISERS INC | 0 | 823,336 | 0 | 0 | Against |
| Putnam | 0 | 816,540 | 0 | 0 | Against |
| Capital Group | 43 | 793,300 | 0 | 0 | Against |
| Freshford Capital Management, LLC | 781,907 | 0 | 0 | 0 | For |
| State Street | 721,946 | 43,436 | 0 | 0 | Mixed |
| NEW YORK STATE COMMON RETIREMENT FUND | 0 | 560,457 | 0 | 0 | Against |
| Northern Trust | 532,827 | 64 | 0 | 0 | For |
| Meritech Capital Associates V L.L.C. | 0 | 0 | 494,236 | 0 | Abstain |
| Sands Capital Ventures, LLC | 481,770 | 0 | 0 | 0 | For |
| BOSTON MANAGEMENT & RESEARCH | 0 | 467,079 | 0 | 0 | Against |
| Newton Investment Management North America, LLC | 0 | 456,140 | 0 | 0 | Against |
Institutional-manager reports, all 291 managers: 30,220,671 for, 31,993,744 against, 30,065 withheld, 503,687 abstained, 9,803 not voted, 46 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 100.0% for (June 14, 2023 meeting) unchanged
Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
10X GENOMICS INC.’s own tally for this item (“2. Ratification of Independent Registered Public Accounting Firm”): 228,845,897 for, 174,119 against — passed, per its Form 8-K filed June 13, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 77 asset managers below reported 47,178,492 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 14,977,374 | 0 | 0 | 0 | For |
| Vanguard | 10,384,989 | 0 | 0 | 0 | For |
| ARK ETF Trust | 6,004,325 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,881,668 | 0 | 0 | 0 | For |
| BlackRock | 1,706,915 | 0 | 0 | 0 | For |
| Morgan Stanley | 1,614,212 | 0 | 0 | 0 | For |
| Brown Capital Management Mutual Funds | 1,249,511 | 0 | 0 | 0 | For |
| Charles Schwab | 940,460 | 0 | 0 | 0 | For |
| Capital Group | 793,300 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 691,105 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 648,000 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 418,141 | 0 | 0 | 0 | For |
| BNY Mellon | 408,754 | 0 | 0 | 0 | For |
| ALGER FUNDS | 360,492 | 0 | 0 | 0 | For |
| Transamerica | 297,184 | 0 | 0 | 0 | For |
| Voya | 287,987 | 0 | 0 | 0 | For |
| TIAA | 249,365 | 0 | 0 | 0 | For |
| BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND) | 240,000 | 0 | 0 | 0 | For |
| Equitable | 197,293 | 0 | 0 | 0 | For |
| Putnam | 191,656 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 158,214 | 0 | 0 | 0 | For |
| Jackson National | 143,557 | 0 | 0 | 0 | For |
| Russell Investments | 138,599 | 0 | 0 | 0 | For |
| Brighthouse | 127,006 | 0 | 0 | 0 | For |
| John Hancock | 117,462 | 0 | 0 | 0 | For |
Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 119,095,362 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 12.58% |
| 2 | Vanguard | 8.72% |
| 3 | ARK ETF Trust | 5.04% |
| 4 | T. Rowe Price | 3.26% |
| 5 | BlackRock | 1.43% |
| 6 | Morgan Stanley | 1.36% |
| 7 | Brown Capital Management Mutual Funds | 1.05% |
| 8 | Charles Schwab | 0.79% |
| 9 | Capital Group | 0.67% |
| 10 | TOUCHSTONE FUNDS GROUP TRUST | 0.58% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 14.26% |
| 2 | T. Rowe Price | 4.51% |
| 3 | BAILLIE GIFFORD & CO LTD | 3.23% |
| 4 | Nikko Asset Management Americas, Inc. | 3.20% |
| 5 | Morgan Stanley | 2.91% |
| 6 | BlackRock | 2.18% |
| 7 | SANDS CAPITAL MANAGEMENT, LLC | 1.92% |
| 8 | BAILLIE GIFFORD OVERSEAS LTD | 1.59% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.37% |
| 10 | BROWN CAPITAL MANAGEMENT LLC | 1.34% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Vanguard Group | 13,274,332 | 11.15% | Form 13F, quarter ended March 31, 2024 |
| BlackRock | 9,460,109 | 7.94% | Form 13F, quarter ended March 31, 2024 |
| FMR (Fidelity) | 8,458,001 | 7.10% | Form 13F, quarter ended March 31, 2024 |
| T. Rowe Price | 3,657,227 | 3.07% | Form 13F, quarter ended March 31, 2024 |
| Morgan Stanley | 2,817,242 | 2.37% | Form 13F, quarter ended March 31, 2024 |
| Goldman Sachs | 2,675,327 | 2.25% | Form 13F, quarter ended March 31, 2024 |
| Geode Capital | 1,643,153 | 1.38% | Form 13F, quarter ended March 31, 2024 |
| State Street | 1,585,702 | 1.33% | Form 13F, quarter ended March 31, 2024 |
| Millennium Management | 1,162,428 | 0.98% | Form 13F, quarter ended March 31, 2024 |
| JPMorgan Chase | 1,073,865 | 0.90% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 119,095,362 shares outstanding, as reported by 10X GENOMICS INC. on its Form 10-K dated December 31, 2023 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At 10X GENOMICS INC.'s shareholder meeting held June 11, 2024, in the 2023-2024 proxy season, 347 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,572 separate fund positions. On the most widely held item on that ballot — A vote to approve, on a non-binding, advisory basis, the compensation of our named executive… — 10X GENOMICS INC.'s filing reports the proposal as approved, with 83% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: 10X GENOMICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 13, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from 10X GENOMICS INC.’s 10-K dated December 31, 2023. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
10X GENOMICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “10X GENOMICS (TXG) 2024 Annual Meeting: Vote Results & How Funds Voted”, https://proxyvotesnow.com/company/10x-genomics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.